Photo

Photo detail

Stories this photo appears in:

Top Billing for Allergan Name

The Allergan name will remain the calling card of the company that will be formed after the Irvine-based drug maker’s estimated $69 billion acquisition by Dublin-based Actavis Plc.

Tease photo

Federal Judge Grants Allergan Injunction Hearing Request

Allergan Inc. said today that a federal judge has set an Oct. 28 hearing for a preliminary injunction against hostile suitors Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman’s Pershing Square Capital Management LP.

Tease photo

Federal Judge Grants Allergan Injunction Hearing Request

Allergan Inc. said today that a federal judge has set an Oct. 28 hearing for a preliminary injunction against hostile suitors Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman’s Pershing Square Capital Management LP.

Tease photo

Allergan Board Rejects Valeant Bid

Irvine-based drug maker Allergan Inc. today rejected a hostile $46 billion takeover bid by Valeant Pharmaceuticals International Inc.

Tease photo

Financial Times: Allergan to Reject Valeant Bid

Irvine-based drug maker Allergan Inc. could reject a hostile $47 billion takeover bid by Valeant Pharmaceuticals International Inc. as early as Monday, according to a report today by the Financial Times.

Tease photo

Allergan Investor Touts Valeant’s ‘Superior’ Bid in Letter

Irvine-based Allergan Inc. should “make the best possible deal” with Canada’s Valeant Pharmaceuticals International Inc. or identify a “superior transaction with another company,” activist investor Bill Ackman said Monday.

Tease photo

Bloomberg: Allergan Looking at Sale

Irvine-based drug maker Allergan Inc. has contacted Johnson & Johnson and France’s Sanofi SA to see if either company would be interested in buying it, according to a Bloomberg report.

Tease photo

Bid for Allergan Now ‘Hostile’

Valeant Pharmaceuticals International Inc. will take its bid for Allergan Inc. directly to the Irvine-based drug maker’s shareholders.

Tease photo